Opioid Withdrawal Management Market Development Status, Competition Analysis, Type and Application 2028

A Opioid withdrawal management, is the treatment with drugs to manage and reduce the intensity of bio physiological withdrawal symptoms associated with dependence or addiction to opioids and to reduce the chances of relapse. Addiction is the compulsive and uncontrollable use of drugs for non-medical uses despite adverse consequences. Dependence is the adaption of body to the presence of a drug, resulting in withdrawal symptoms when drug use is discontinued.

The physiological opioid withdrawal symptoms include Muscle aches, pain, spasms, Involuntary movements, Mild hypertension, and others. The psychological opioid withdrawal symptoms include agitation, anxiety, panic, restlessness, rapid heart rate, seizures, fear, paranoia and others. Thus opioid withdrawal management aids the patient to avoid relapsing and to quit opioid addiction and dependence with minimal discomfort.

Opioid Withdrawal Management Market: Drivers and Restraints

The explosive use of opioids for management of pain, opioid abuse resulting from illegal use coupled with the perverse incentives and misdirection by pharmaceutical pain management companies are the driving factors for the market.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-7672 

The National Institute on Drug Abuse and the Centers for Disease Control and Prevention, have declared that the U.S. is in the midst of an opioid epidemic. U.S. consumes about 80% of global opioids although it has less than 5 % of the world’s population. Concerns about Opioid overdose related deaths which accounted for 49,000 of the 72,000 drug overdose deaths in the U.S. in 2017 alone has generated a lot of market enthusiasm. According to the center of disease control, around 66% of the more than 63,600 drug overdose deaths in 2016 involved an opioid and on average, 115 Americans die every day from an opioid overdose

This has resulted in a cry from the media resulting in growing stringency of regulations. According to the center of disease control, the sharpest increase among the 72,000 drug overdose deaths in 2017, were related to fentanyl and analogs at nearly 30,000. The development of withdrawal clinics and the growing success of opioid withdrawal treatment especially the development of non-opioid drugs for the treatment and mitigation of opioid withdrawal symptoms is driving a faster adoption. Work place policies such as zero tolerance policies for substance abuse, regular check-ups and screening is another driver of the market.

The unfortunate reality of the prospering drug trade traversing international borders, the spread of heroin abuse has further stimulated the market. According to the national institute of drug abuse, almost 2.1 million people in the U.S. suffer from prescription opioid pain medicines related substance use disorder related in 2016 with only 17.5 percent receiving treatment.

A large market enthusiasm has been generated by the approval of lofexidine, the first drug intended for reducing symptoms associated with opioid withdrawal by the U.S. Food and Drug Administration. However, the social stigma associated with opioid addiction, discriminating and strict workplace rules and the lower success rate of Opioid withdrawal management is hampering the market.